stage

Country: Netherlands

Bone Reinforcement

Bone Reinforcement

location_on North Western , Switzerland

Overview Pitch Details The Team Documents

Please note:
Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. Investors are encouraged to review and evaluate the investments and determine at their own discretion, the appropriateness of making the particular investment. The information on this website is provided for informational purposes only, but we cannot guarantee that the information is accurate or complete. We strongly encourage investors to complete their own due diligence with licensed professionals, prior to making any investment and will not offer any legal or tax advice.

Short Summary

NX-Spine is advancing bone enhancement to improve spinal fusion outcomes with a cost-effective platform technology that rapidly reinforces bone to optimize screw stability. Efficacy is equivalent to PMMA but is faster and safer.

Highlights

Our system has been successfully used in European clinical trials
Surgeons and strategics all acknowledge the risk of pedicle screw loosening
Other applications are promising: pediatric scoliosis.
The FDA supports the pathway, the predicate device, and the study.
Strong IP and FTO successfully executed removing risk from US launch.

Overview

Target	€6,400,000
Minimum	€100,000
Investment Raised	€1,100,000
Previous Rounds	€5,300,000
Stage	MVP/Finished Product
Investor Role	Any

Ask a question
Have a question?

Similar Projects

Entac Medical Inc.

location_onSouth East, United States

Entac develops AI-driven acoustic wearables predicting patient adverse events, with its first launched device, PrevisEA, targeting an $8 billion market and a pipeline for multiple high-value healthcare sectors exceeding $20 billion.

PrevisEA Commitments: 5 hospitals systems (63 hospitals) $41M revenue oppy
In review: 6 systems (71 hospitals) - $39M opportunity. Commitment due
Engaged: 7 systems (120 hospitals) - $67M opportunity - Expected in 2025.

€1,700,000

Total Required

€45,000

Min per Investor

Reducing Heart Attacks

location_onZurich, Switzerland

HeartForce’s patented technology allows doctors to place a handheld, non-invasive device on a patient’s chest. It monitors ECG output and assesses arterial blockages. This precise and cost-effective tool could save countless lives.

Patented technology that will help to reduce the mortality rate
Non-invasive and much more cost effective than any other method
HeartForce’s first mover advantage implies there is no direct competition

€14,000,000

Total Required

€55,000

Min per Investor